Method of treating inflammatory disorder with antibodies directed against interleukin-33 (IL-33)
US10836820B2 · kind B2 · utility
1Cited by
27References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 23, 2018 |
| Grant date | Nov 17, 2020 |
| Priority date | — |
| Expiry date | Jul 23, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.